Dexcel Pharma's portfolio consists of over 60 products in more than 140 dosages, with projected 2009 sales of 3.9 billion tablets/capsules totaling US$240 milllion. Around 80% of sales are to the large international markets. Projected sales in 2010 are 5.4 billion tablets/capsules totaling US$260 million.

Dexcel Pharma is the second largest Israeli pharmaceutical manufacturer, both in value and quantities -  it supplies 25% of the local market, well ahead of any other player.

Dexcel Pharma's corporate HQ, R&D and manufacturing facilities are in Or Akiva, Israel, with a smaller manufacturing unit in Jerusalem. An adjacent packaging facility in Or Akiva and a state of the art, 5-floor gravity - feed, paperless electronic manufacturing facility in nearby Yokneam - representing an investment of US$61 million - are under construction, with both expected to be operational by early 2010.

Dexcel Pharma's world class manufacturing facilities will, by early 2010, comprise a total of 467,000 square feet - 43,380 square meters - at 3 locations, including:

• An expansion in Or Akiva.
• A new, state of the art, 5-floor gravity feed, paperless electronic manufacturing plant in Yokneam.
• In Jerusalem.

Dexcel Pharma's total new investment in its manufacturing facilities: US$61 million.

Dexcel Pharma's manufacturing forecast for tablets/capsules is 3.9 billion in 2009 and 5.4 billion in 2010.

Dexcel Pharma employs cutting-edge, computer-controlled manufacturing technology - including a recently installed electronic batch recording -  facilitating optimization of production and a reduction in human error.

Dexcel Pharma's manufacturing facilities, and their operations are approved by the US FDA, UK MHRA and the German authorities, and meet or exceed all FDA and EU Good Manufacturing Practices (cGMP).

Dexcel Pharma offers flexible and responsive service, on-time delivery, competitive pricing, efficient technical transfer and inventory coverage, and global supply chain management services.

Core Sales Territory: Global Regulated Markets

Core Operation: API Manufacture, Finished Dose Manufacture, Sales and Marketing

Number of molecules sold: > 40

Company's rating: